Safety and Efficacy study of QVM149 in asthmatic patients

• Register: EUCTR
• Last refreshed on: 25 November 2019
• Main ID: EUCTR2015-002899-25-AT
• Date of registration: 15/12/2015
• Prospective Registration: Yes
• Primary sponsor: Novartis Pharma Services AG
• Public title: Safety and Efficacy study of QVM149 in asthmatic patients
• Scientific title: A multicenter, randomized, 52-week, double-blind, parallelgroup, active controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma - Safety and Efficacy study of QVM149 in asthmatic patients
• Date of first enrolment: 15/03/2016
• Target sample size: 2980
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002899-25
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes; Randomised: yes; Open: no; Single blind: no; Double blind: yes; Parallel group: yes; Cross over: no; Other: yes; Other trial design description: double-dummy; If controlled, specify comparator, Other Medicinial Product: yes; Placebo: yes; Other: no; Number of treatment arms in the trial: 5
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no

Countries of recruitment

Anguilla, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Denmark, Estonia, Ethiopia, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Jordan, Latvia, Lebanon, Lithuania, Luxembourg, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Thailand, United Arab Emirates, United Kingdom, Vietnam

Contacts

• Name: Drug Regulatory Affairs
• Affiliation: Novartis Pharma GmbH

• Name: Drug Regulatory Affairs
• Affiliation: Novartis Pharma GmbH

Key inclusion & exclusion criteria

Inclusion criteria:
Section E3.
- Patients with a diagnosis of asthma, (GINA 2015) for a period of at least 1 year prior to Visit 1 (Screening).
-Patients who have used medium or high dose of ICS/LABA combinations for asthma for at least 3months and at stable medium or high doses of ICS/LABA for at least 1 month prior to Visit 1. Patients must be symptomatic at screening despite treatment with mid or high stable doses of ICS/LABA.
- Patients with ACQ-7 score = 1.5 at Visit 101 and at Visit 102 (before randomization) (GINA 2015).
- Patients with documented history of at least one asthma exacerbation which required medical care from a physician, ER visit (or local equivalent structure) or hospitalization in the 12 months prior to Visit 1, and required systemic corticosteroid treatment.
-Pre-bronchodilator FEV1 of < 80 % of the predicted normal value for the patient according to ATS/ERS guidelines after withholding bronchodilators at both visits 101 and 102.
-Withholding period of bronchodilators prior to spirometry: SABA for = 6 hrs, Twice daily LABA (or FDC of ICS/LABA) for = 12 hrs, Once daily LABA (or FDC of ICS/LABA) for = 24 hrs, SAMA for = 8 hrs, Short acting xanthines for 12 hrs, Long acting xanthines for 24 hrs .
-Washout period of each drug should be kept as closed as possible as above and should not be longer. If longer washout period is needed due to scheduling issues, please contact Novartis Medical monitor.
-A one time repeat of percentage predicted FEV1 (Pre-bronchodilator) at visit 101 and/or 102 is allowed in and ad hoc visit. Repeat of visit 101 spirometry should be done in an ad-hoc visit to be scheduled on a date that would provide sufficient time to receive confirmation from the spirometry data central reviewer of the validity of the assessment before randomization. Run-in medication should be dispensed once spirometry assessment met inclusion criteria (ATS/ERS quality criteria, FEV1 % predicted normal value, and reversibility) as per equipment.
- A one-time rescreen is allowed in case the patient fails to meet the criteria at the repeat, provided the patient returned to the required treatment as per inclusion criteria 4
-Patients who demonstrate an increase in FEV1 of 12% and 200 mL within 30 minutes after administration of 400 µg salbutamol/360 µg albuterol (or equivalent dose) at Visit 101.All patients must perform a reversibility test at Visit 101. If reversibility is not demonstrated at Visit 101 then one of the following criteria need to be met.
-Reversibility should be repeated once.
-Patients may be permitted to enter the study with historical evidence of reversibility that was performed according to ATS/ERS guidelines within 2 years prior to Visit 1.
-Alternatively, patients may be permitted to enter the study with a historical positive bronchoprovocation test that was performed within 2 years prior to Visit 1. If reversibility is not demonstrated at Visit 101 (or after repeated assessment in an ad-hoc visit) and historical evidence of reversibility/bronchoprovocation is not available (or was not performed according to ATS/ERS guidelines patients must be screen failed
-Spacer devices are permitted during reversibility testing only. Investigator or delegate may decide whether or not to use a spacer for the reversibility testing.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 2830
F.1.3 Elderly (>=65 years) yes
F
Exclusion criteria:
- Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening). If patients experience an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit between Visit 1 and Visit 102 they may be re-screened 6 weeks after recovery from the exacerbation.
- Patients who have ever required intubation for a severe asthma attack/exacerbation.
- Patients who have a clinical condition which is likely to be worsened by ICS administration (e.g. glaucoma, cataract and fragility fractures) who are according to investigator's medical judgment at risk participating in the study.
- Patients treated with a LAMA for asthma within 3 months prior Visit 1 (Screening).
- Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or bladder-neck obstruction or severe renal impairment or urinary retention. BPH patients who are stable on treatment can be considered).
- Patients who have had a respiratory tract infection or asthma worsening as determined by investigator within 4 weeks prior to Visit 1 (Screening) or between Visit 1 and Visit 102. Patients may be re-screened 4 weeks after recovery from their respiratory tract infection or asthma worsening.
- Patients with evidence upon visual inspection (laboratory culture is not required) of clinically significant (in the opinion of investigator) oropharyngeal candidiasis at Visit 102 or earlier, with or without treatment. Patients may be rescreened once their candidiasis has been treated and has resolved.
- Patients with any chronic conditions affecting the upper respiratory tract (e.g. chronic sinusitis) which in the opinion of the investigator may interfere with the study evaluation or optimal participation in the study.
- Patients with a history of chronic lung diseases other than asthma, including (but not limited to) chronic obstructive pulmonary disease, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.
- Patients with Type I diabetes or uncontrolled Type II diabetes.
- Patients who, either in the judgment of the investigator or the responsible Novartis personnel, have a clinically significant condition such as (but not limited to) unstable ischemic heart disease, New York Heart Association (NYHA) Class III/IV left ventricular failure arrhythmia, uncontrolled hypertension, cerebrovascular disease, psychiatric disease, neurodegenerative diseases, or other neurological disease, uncontrolled hypo- and hyperthyroidism and other autoimmune diseases, hypokalemia, hyperadrenergic state, or ophthalmologic disorder or patients with a medical condition that might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study.
- Patients with paroxysmal (e.g., intermittent) atrial fibrillation are excluded. Patients with persistent atrial fibrillation as defined by continuous atrial fibrillation for at least 6 months and controlled with a rate control strategy (i.e., selective beta blockers, calcium channel blocker, pacemaker placement, digoxin or ablation therapy) for at least 6 months may be considered for inclusion. In such patients, atrial fibrillation must be present at the run-in visit (Visit 101) with a resting ventricular rate < 100/min. At Visit 101 the atrial fibrillation must be confirmed by central reading.
- Patients with a

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Asthma
MedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders

Intervention(s)

Product Name: Indacaterol acetate / Glycopyrronium bromide/ Mometasone furoate/
Product Code: QVM149
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: Indacaterol acetate
Other descriptive name: INDACATEROL ACETATE
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 150-
INN or Proposed INN: Mometasone Furoate
Other descriptive name: MOMETASONE FUROATE
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 80-
INN or Proposed INN: GLYCOPYRRONIUM BROMIDE
CAS Number: 596-51-0
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Inhalation powder, hard capsule
Route of administration of the placebo: Inhalation use

Product Name: Indacaterol acetate /Glycopyrronium bromide/Mometasone furoate
Product Code: QVM149
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: Indacaterol acetate
Other descriptive name: INDACATEROL ACETATE
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 150-
INN or Proposed INN: Mometasone furoate
Other descriptive name: MOMETASONE FUROATE
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 160-
INN or Proposed INN: GLYCOPYRRONIUM BROMIDE
CAS Number: 596-51-0
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Inhalation powder, hard capsule
Route of administration of the placebo: Inhalation use

Product Name: Indacaterol acetate/ Mometasone furoate
Product Code: QMF149
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: INDACATEROL ACETATE
Other descriptive name: INDACATEROL ACETATE
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 150-
INN or Proposed INN: Mometasone furoate
Other descriptive name: MOMETASONE FUROATE
Concentration unit: µg microgram(s)
Concentration type: equal
Co

Primary Outcome(s)

Primary end point(s): To demonstrate superiority of either QVM149 doses to either QMF doses on through FEV1 over 26 weeks of treatment.

Main Objective: to demonstrate superiority of
either QVM149 150/50/80 µg
o.d. to QMF149 150/160 µg
o.d. or QVM149 150/50/160
µg o.d. to QMF149 150/320
µg o.d on through FEV1 over
26 weeks of treatment. Forced
Expiratory cvolume in 1
second (FEV1) is the amount
of air which can be forcibly
exhaled from the lungs in the
first second of a forced
exhalation, measured through
spirometry testing.

Secondary Objective: - Through FEV1 over 52 weeks
- FEV1 and FVC at weeks 4 and 12
- PEF at weeks 26 and 52
- ACQ-7 at 26 and 52 weeks
- Percentage days with no symptoms (overall, at awakening and rising) at 52 weeks
- Percentage days without rescue medication use over 26 weeks and 52 weeks
- Percentage of patients with MID ACQ>= 0.5 at week 26 and 52
- Asthma exacerbations over 52 weeks
-percentage of rescue medication free days over 26 and 52 weeks
- AQLQ at 52 weeks (at all clinical visits)
- Through FEV1 at 26 weeks comparison with salmeterol xinafoate/fluticasone proprionate 50/500µg via Accuhaler®
- Asthma control as assessed by the ACQ-7 comparison with salmeterol xinafoate/fluticasone proprionate 50/500µg via Accuhaler® at 26 weeks
- Serious asthma outcome incidence and CCV events/atrial fibrilation at 52 weeks
- Adverse events, vital sighns, laboratory analysis and ECG at 52 weeks

Timepoint(s) of evaluation of this end point: 26 weeks

Secondary Outcome(s)

Timepoint(s) of evaluation of this end point: 26 weeks

Secondary end point(s): To demonstrate superiority of either QVM149 doses to either QMF149 doses ACQ-7

Secondary ID(s)

NCT02571777

2015-002899-25-EE

CQVM149B2302

Source(s) of Monetary Support

Novartis Pharma Services AG

Ethics review

Status: Approved
Approval date:
Contact: